Biocartis Group NV

OTCPK:BIOG.F Stock Report

Market Cap: US$63.6m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Biocartis Group Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Herman Verrelst

Chief executive officer

€495.1k

Total compensation

CEO salary percentage75.7%
CEO tenure5.6yrs
CEO ownershipn/a
Management average tenure5.6yrs
Board average tenure5.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Herman Verrelst's remuneration changed compared to Biocartis Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2022n/an/a

-€48m

Sep 30 2022n/an/a

-€55m

Jun 30 2022n/an/a

-€63m

Mar 31 2022n/an/a

-€67m

Dec 31 2021€495k€375k

-€71m

Sep 30 2021n/an/a

-€70m

Jun 30 2021n/an/a

-€69m

Mar 31 2021n/an/a

-€66m

Dec 31 2020€502k€375k

-€63m

Sep 30 2020n/an/a

-€64m

Jun 30 2020n/an/a

-€66m

Mar 31 2020n/an/a

-€65m

Dec 31 2019€448k€375k

-€64m

Sep 30 2019n/an/a

-€60m

Jun 30 2019n/an/a

-€56m

Mar 31 2019n/an/a

-€52m

Dec 31 2018€510k€375k

-€48m

Sep 30 2018n/an/a

-€44m

Jun 30 2018n/an/a

-€40m

Mar 31 2018n/an/a

-€41m

Dec 31 2017€232k€137k

-€42m

Compensation vs Market: Herman's total compensation ($USD526.77K) is about average for companies of similar size in the US market ($USD740.57K).

Compensation vs Earnings: Herman's compensation has been consistent with company performance over the past year.

CEO

Herman Verrelst (48 yo)

5.6yrs

Tenure

€495,058

Compensation

Mr. Herman Verrelst serves as Director at FOx Diagnostics. He has been Chief Executive Officer of Biocartis Group NV since August 31, 2017. Mr. Verrelst served as the President of the Board at FOx Diagnost...

Leadership Team

NamePositionTenureCompensationOwnership
Herman Verrelst
CEO & Executive Director5.6yrs€495.06kno data
Jean-Marc Roelandt
Chief Financial Officer2.9yrsno datano data
Piet Houwen
Chief Operating Officer3.9yrsno datano data
Benoit Devogelaere
Chief Technology Officer5.3yrsno datano data
Geert Maertens
Chairman of Scientific Advisory Board & Chief Scientific Officerno datano datano data
Renate Degrave
Head of IR & Corporate Communicationsno datano datano data
Susy Spruyt
Head of People & Organization8.2yrsno datano data
Erwin Sablon
Head of R&D and Alliance Management10.6yrsno datano data
Reginald Van Genechten
Head of Manufacturing & Supply Chain7yrsno datano data
Dirk Zimmermann
Global Head of Pharma Collaborations & Partnering3.8yrsno datano data
Erik Vossenaar
Vice President of Business Development7.2yrsno datano data

5.6yrs

Average Tenure

54yo

Average Age

Experienced Management: BIOG.F's management team is seasoned and experienced (5.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Herman Verrelst
CEO & Executive Director5.5yrs€495.06kno data
Geert Maertens
Chairman of Scientific Advisory Board & Chief Scientific Officerno datano datano data
Christian Reinaudo
Independent Chairman of the Board4.8yrs€81.00kno data
Jean-Louis Vincent
Member of Scientific Advisory Boardno datano datano data
Ann-Christine Sundell
Non Executive Independent Director5.2yrs€43.50kno data
Pasi Antero Janne
Member of Scientific Advisory Boardno datano datano data
Alberto Bardelli
Member of Scientific Advisory Boardno datano datano data
Eric Cutsem
Member of Scientific Advisory Boardno datano datano data
Josep Tabernero
Member of Scientific Advisory Boardno datano datano data
Bert Niesters
Member of Scientific Advisory Boardno datano datano data
Luc Gijsens
Non-Executive Independent Director5.2yrs€46.00kno data
Michael Press
Member of Scientific Advisory Boardno datano datano data

5.2yrs

Average Tenure

64yo

Average Age

Experienced Board: BIOG.F's board of directors are considered experienced (5.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/03/12 19:16
End of Day Share Price 2022/12/13 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biocartis Group NV is covered by 7 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Scott BardoBerenberg
Hugo SolvetBryan Garnier & Co
Guy SipsKBC Securities NV